BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Villani R, Vendemiale G, Serviddio G. Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy. Int J Mol Sci 2018;20:E49. [PMID: 30583555 DOI: 10.3390/ijms20010049] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. Lancet. 2019;394:1451-1466. [PMID: 31 DOI: 10.1016/s0140-6736(19)32320-7] [Cited by in Crossref: 108] [Cited by in F6Publishing: 56] [Article Influence: 2.3] [Reference Citation Analysis]
2 Foka P, Dimitriadis A, Karamichali E, Kochlios E, Eliadis P, Valiakou V, Koskinas J, Mamalaki A, Georgopoulou U. HCV-Induced Immunometabolic Crosstalk in a Triple-Cell Co-Culture Model Capable of Simulating Systemic Iron Homeostasis. Cells 2021;10:2251. [PMID: 34571900 DOI: 10.3390/cells10092251] [Reference Citation Analysis]
3 Peng L, Ye R, Zhu X, Xie Y, Zhong B, Liu Y, Li H, Xie B, Ortega A. LINC02273 Promotes Hepatocellular Carcinoma Progression via Retaining β-Catenin in the Nucleus to Augment Wnt Signaling. BioMed Research International 2022;2022:1-9. [DOI: 10.1155/2022/9631036] [Reference Citation Analysis]
4 Kamal A, Elmoety AAA, Rostom YA, Shater MS, Lashen SA. Hepatocellular carcinoma recurrence after directly acting antivirals for chronic hepatitis C: a 2-year follow-up study. Clin Exp Hepatol 2021;7:66-73. [PMID: 34027117 DOI: 10.5114/ceh.2021.104397] [Reference Citation Analysis]
5 Kamal A, Elsheaita A, Abdelnabi M. Association between direct-acting antiviral agents in hepatitis C virus treatment and hepatocellular carcinoma occurrence and recurrence: The endless debate. World J Clin Cases 2022; 10(6): 1764-1774 [DOI: 10.12998/wjcc.v10.i6.1764] [Reference Citation Analysis]
6 Omran M, Fouda M, Abdelwahab AO, Nabeel MM, Abdelaziz AO, Omran D, Shousha HI. P53 is a risk factor of de-novo hepatitis C-related hepatocellular carcinoma treated with direct-acting antivirals: a case-control study. Eur J Gastroenterol Hepatol 2022;34:220-6. [PMID: 33079785 DOI: 10.1097/MEG.0000000000001962] [Reference Citation Analysis]
7 Khatun M, Ray R, Ray RB. Hepatitis C virus associated hepatocellular carcinoma. Adv Cancer Res 2021;149:103-42. [PMID: 33579422 DOI: 10.1016/bs.acr.2020.10.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Li J, Yan K, Yang Y, Li H, Wang Z, Xu X. [Musashi-1 positively regulates growth and proliferation of hepatoma cells in vitro]. Nan Fang Yi Ke Da Xue Xue Bao 2019;39:1436-42. [PMID: 31907147 DOI: 10.12122/j.issn.1673-4254.2019.12.07] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Hsu SJ, Yang SS, Kao JH. Risk of hepatocellular carcinoma development after hepatitis C virus eradicated by direct-acting antivirals: Fact or fiction? J Formos Med Assoc 2020;119:3-11. [PMID: 31627984 DOI: 10.1016/j.jfma.2019.09.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
10 Kamal MM, Abdelaziz AO, El-Baz HN, Mohamed GM, Saleh SS, Nabeel MM, Elbaz TM, Lithy R, Shousha HI. Plasma cell-free DNA integrity index and hepatocellular carcinoma treated or not with direct-acting antivirals: A case-control study. Arab J Gastroenterol 2022:S1687-1979(21)00100-3. [PMID: 35120838 DOI: 10.1016/j.ajg.2021.12.006] [Reference Citation Analysis]
11 Tai CJ, Jassey A, Liu CH, Tai CJ, Richardson CD, Wong SH, Lin LT. Targeting Autophagy Augments BBR-Mediated Cell Death in Human Hepatoma Cells Harboring Hepatitis C Virus RNA. Cells 2020;9:E908. [PMID: 32276448 DOI: 10.3390/cells9040908] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Kishta S, Tabll A, Omanovic Kolaric T, Smolic R, Smolic M. Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals. Biomedicines 2020;8:E175. [PMID: 32630610 DOI: 10.3390/biomedicines8060175] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Lin S, Lin Y, Wu Z, Xia W, Miao C, Peng T, Zhao Z, Ji C, Mo Z, Liu X, Jian Z. circRPS16 Promotes Proliferation and Invasion of Hepatocellular Carcinoma by Sponging miR-876-5p to Upregulate SPINK1. Front Oncol 2021;11:724415. [PMID: 34595116 DOI: 10.3389/fonc.2021.724415] [Reference Citation Analysis]
14 Sangineto M, Villani R, Cavallone F, Romano A, Loizzi D, Serviddio G. Lipid Metabolism in Development and Progression of Hepatocellular Carcinoma.Cancers (Basel). 2020;12. [PMID: 32486341 DOI: 10.3390/cancers12061419] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
15 Kurosaki K, Uesawa Y. Molecular Initiating Events Associated with Drug-Induced Liver Malignant Tumors: An Integrated Study of the FDA Adverse Event Reporting System and Toxicity Predictions. Biomolecules 2021;11:944. [PMID: 34202146 DOI: 10.3390/biom11070944] [Reference Citation Analysis]
16 Sung PS, Shin EC. Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection. J Clin Med 2021;10:E221. [PMID: 33435135 DOI: 10.3390/jcm10020221] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
17 Kishta S, Tabll A, Omanovic Kolaric T, Smolic R, Smolic M. Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals. Biomedicines 2020;8:E175. [PMID: 32630610 DOI: 10.3390/biomedicines8060175] [Reference Citation Analysis]
18 Sanduzzi-Zamparelli M, Boix L, Leal C, Reig M. Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents. Viruses 2019;11:E406. [PMID: 31052463 DOI: 10.3390/v11050406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
19 Yao Z, Xu R, Yuan L, Xu M, Zhuang H, Li Y, Zhang Y, Lin N. Circ_0001955 facilitates hepatocellular carcinoma (HCC) tumorigenesis by sponging miR-516a-5p to release TRAF6 and MAPK11. Cell Death Dis 2019;10:945. [PMID: 31822654 DOI: 10.1038/s41419-019-2176-y] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 12.3] [Reference Citation Analysis]
20 Chen Y, Fu H, Zhang Y, Chen P. Transmembrane and Ubiquitin-Like Domain Containing 1 Protein (TMUB1) Negatively Regulates Hepatocellular Carcinoma Proliferation via Regulating Signal Transducer and Activator of Transcription 1 (STAT1). Med Sci Monit 2019;25:9471-82. [PMID: 31827061 DOI: 10.12659/MSM.920319] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
21 Guo W, Zhao L, Wei G, Liu P, Zhang Y, Fu L. Circ_0015756 Aggravates Hepatocellular Carcinoma Development by Regulating FGFR1 via Sponging miR-610. Cancer Manag Res 2020;12:7383-94. [PMID: 32884351 DOI: 10.2147/CMAR.S262231] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Teng W, Liu YC, Jeng WJ, Su CW. Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients. Cancers (Basel) 2021;13:1729. [PMID: 33917345 DOI: 10.3390/cancers13071729] [Reference Citation Analysis]
23 Yasser MB, Abdellatif M, Emad E, Jafer A, Ahmed S, Nageb L, Abdelshafy H, Al-Anany AM, Al-Arab MAE, Gibriel AA. Circulatory miR-221 & miR-542 expression profiles as potential molecular biomarkers in Hepatitis C Virus mediated liver cirrhosis and hepatocellular carcinoma. Virus Res 2021;296:198341. [PMID: 33607184 DOI: 10.1016/j.virusres.2021.198341] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]